Furazolidone
Furoxone (furazolidone) is a small molecule pharmaceutical. Furazolidone was first approved as Furoxone on 1982-01-01. It is used to treat animal salmonella infections, bacillary dysentery, cholera, diarrhea, and enteritis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AX: Other gynecological antiinfectives and antiseptics in atc
— G01AX06: Furazolidone
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01A: Agents against amoebiasis and other protozoal diseases
— P01AB: Nitroimidazole derivatives, antiprotozoal agents against amoebiasis and other protozoal diseases
— P01AB51: Metronidazole and furazolidone
HCPCS
No data
Clinical
Clinical Trials
44 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | 1 | 15 | 11 | 29 |
| Helicobacter infections | D016481 | EFO_1000961 | — | 1 | 1 | 1 | 9 | 6 | 17 |
| Gastritis | D005756 | EFO_0000217 | K29.7 | — | — | — | 6 | 3 | 9 |
| Communicable diseases | D003141 | — | — | — | — | — | 5 | 4 | 9 |
| Disease susceptibility | D004198 | — | — | — | — | — | 6 | — | 6 |
| Peptic ulcer | D010437 | HP_0004398 | K27 | — | — | — | 3 | 1 | 4 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | 3 | — | 3 |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | 3 | — | 3 |
| Ulcer | D014456 | MPATH_579 | — | — | — | — | 1 | 1 | 2 |
| Stomach ulcer | D013276 | — | K25 | — | — | — | 1 | 1 | 2 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 1 | 1 | — | — | 1 |
| Thrombocytopenic purpura | D011696 | — | — | — | 1 | 1 | — | — | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chinese traditional medicine | D008516 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 1 | 1 |
| Malaria | D008288 | EFO_0001068 | B54 | — | — | — | — | 1 | 1 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Neonatal sepsis | D000071074 | HP_0040187 | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | HP_0002014 | R19.7 | — | — | — | — | 1 | 1 |
| Asphyxia | D001237 | — | R09.01 | — | — | — | — | 1 | 1 |
| Asphyxia neonatorum | D001238 | EFO_1000824 | P84 | — | — | — | — | 1 | 1 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Furazolidone |
| INN | furazolidone |
| Description | Furazolidone is a nitrofuran antibacterial agent and monoamine oxidase inhibitor (MAOI). It is marketed by Roberts Laboratories under the brand name Furoxone and by GlaxoSmithKline as Dependal-M.
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1OCCN1/N=C/c1ccc([N+](=O)[O-])o1 |
Identifiers
| PDB | — |
| CAS-ID | 67-45-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1103 |
| ChEBI ID | — |
| PubChem CID | 3435 |
| DrugBank | DB00614 |
| UNII ID | 5J9CPU3RE0 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Furazolidone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,569 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
219 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use